Reports Q2 revenue $2.53B, consensus $2.49B. “In the second quarter, we achieved our ninth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health (BHC), excluding Bausch + Lomb. This consistent performance highlights our operational excellence and the strength of our diverse portfolio across therapeutic areas and geographies. As we look toward the second half of 2025, we remain focused on executing against our strategic priorities to drive continued growth and unlock long-term value for our shareholders,” said Thomas Appio, CEO, Bausch Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health to acquire Durect for $1.75 per share in cash upfront
- Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction
- Bausch Health to reduce debt by $900M using cash on hand
- Bausch Health appoints Michael Goettler, Sandra Leung to board
- Bausch Health Canada announces CABTREO availability via public drug plans